[ad_1]
The antiviral drug’remdesivir controversy over the efficacy of Corona 19
Approved by the US FDA in May … Korea has also used it since July
WHO “no effect” clinical results “need to review” quarantine authorities are cautious
[앵커]
In relation to the controversy over the efficacy of ” remdesivir, ” which is used as a treatment for Corona 19, quarantine authorities have taken a cautious position and have said the results of the investigation should be further reviewed. He said there is no need to change home treatment guidelines immediately and that it will continue to be administered to seriously ill patients who need oxygen. Reporter Ki Jung-hoon reports. It is an antiviral drug “amdesivir” from Gilead Sciences, an American pharmaceutical company. It was originally a treatment for Ebola, but it is known to be effective for patients with severe corona19. It was urgently approved by the US Food and Drug Administration ‘FDA’ in May, and has been used in Korea since last July, but controversy arose when the results of recent clinical trials of it were released. the World Health Organization (WHO). In a word, the treatment had little effect because neither the mortality rate nor the length of hospitalization was reduced. However, quarantine authorities took a cautious position and said further review is needed. The WHO clinical results that there was no difference in mortality were also known, and explained that 11 cases of side effects that occurred in Korea were not dangerous. The WHO clinical results will be closely reviewed once the review is completed and, to date, maintains guidelines for the delivery of oxygen to critically ill patients. As of 4 pm on the 16th, there are 618 patients in 63 hospitals in Korea who have received remdesivir. YTN Ki Jeong-hoon[[email protected]]is. ※ ‘Your report becomes news’ YTN awaits your valuable report.
[카카오톡] Search YTN to add a channel [전화] 02-398-8585 [메일] [email protected] [온라인 제보] www.ytn.co.kr
